Dr. Grant C Sorkin, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 228 Saint Charles Way Ste 300, York, PA 17402 Phone: 717-812-5400 Fax: 717-741-3598 |
Dr. Arnold G Salotto, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 228 Saint Charles Way Ste 300, York, PA 17402 Phone: 717-812-5400 Fax: 717-741-3598 |
Pawel G Ochalski, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 228 Saint Charles Way Ste 300, York, PA 17402 Phone: 717-812-5400 Fax: 717-741-3598 |
Dr. Joel W Winer, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 228 Saint Charles Way Ste 300, York, PA 17402 Phone: 717-812-5400 Fax: 717-741-3598 |
Dr. Joseph P Krzeminski, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 228 Saint Charles Way Ste 300, York, PA 17402 Phone: 717-812-5400 Fax: 717-741-3598 |
News Archive
Researchers have shown that compared to placebo, a drug treatment intended to prevent remodeling of the bladder wall and given within 48 hours after spinal cord injury (SCI) in dogs was associated with significantly higher bladder compliance.
The current issue of Neurodegenerative Disease Management explores evolving viewpoints on the role of mild cognitive impairment in Parkinson's Disease (PD-MCI), a medical issue which currently lacks consensus. Neurodegenerative Disease Management is published by Future Science Group. The article is also available free of charge to members of Neurology Central, FSG's online community for the international neurology community.
On the upcoming Super Bowl Sunday, a lot of us will be playing arm-chair quarterback. After the snap, we might use our eyes to track a wide receiver as he runs toward an opening, all the while remembering the location of the star running back in case he breaks through on a rushing play. This natural ability to track one moving player but be ready to quickly look back toward another one sounds simple.
A paper that recently appeared in the preprint server bioRxiv* reports the powerful activity of a compound named MEDS433 against this virus.
Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis."
› Verified 7 days ago